Remote ischemic preconditioning for prevention of contrast-induced nephropathy – A randomized control trial

Akshay Ashok Bafna a, *, Hetan C. Shah b

a Department of Cardiology, Rajarshee Chhatrapati Shahu Maharaj Government Medical College and CPR Hospital, Kolhapur, India
b Department of Cardiology, King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Mumbai, India

ARTICLE INFO

Article history:
Received 3 October 2019
Accepted 29 April 2020
Available online 26 May 2020

Keywords:
Coronary angiography
Nephropathy
Percutaneous coronary intervention

Abstract

Background: There is a lack of sufficient data regarding the protective effects of remote ischemic preconditioning (RIPC) in patients at risk of developing contrast-induced nephropathy (CIN). Thus, this study was conducted to determine whether RIPC as an adjunct to standard therapy prevents CIN in high-risk patients undergoing coronary intervention.

Methods: In a single-center, double-blinded, randomized controlled trial, 162 patients who were at risk of CIN received standard hydration combined with RIPC or hydration with sham preconditioning. RIPC was accomplished by four cycles of 5 min ischemia and 5 min reperfusion of the forearm. The primary endpoint was a rise in serum creatinine (>0.5 mg/dL or >25%) from baseline to serum creatinine 48–72 h after contrast administration.

Results: Of the 162 patients, 81 were randomly allocated to receive sham preconditioning and 81 to receive RIPC. Significantly reduced serum creatinine levels were observed in patients with a Mehran moderate risk allocated to sham group compared to the RIPC group (0.070 ± 0.16 mg/dL vs. 0.107 ± 0.13 mg/dL, p = 0.001). With regards to the primary endpoint, a significantly higher change in serum creatinine from baseline to 48–72 h was observed in the sham group compared to the RIPC group (0.023 ± 0.2 μmol/L vs. −0.064 ± 0.1 μmol/L, p < 0.001).

Conclusion: RIPC as an alternative to standard therapy, improved serum creatinine levels after contrast administration in patients at risk of CIN. However, present data indicate that RIPC might have beneficial effects in patients with a moderate or high risk of CIN.

© 2020 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Coronary angiography (CA) and percutaneous coronary intervention (PCI) are routinely performed in patients with coronary artery disease. In the past few years, with the development of clinical diagnosis and interventional therapy, the use of iodine-containing contrast media in PCI is increasing and can lead to contrast-induced nephropathy (CIN). Consequently, CIN has become a common complication of PCI and has become the third leading cause of acute renal failure in hospital. Ongoing techniques to prevent CIN include pre-procedural hydration with isotonic saline, utilization of iso-osmolar non-ionic contrast media, pre-medicating with N-acetyl cysteine, and removal of nephrotoxic drugs. Unfortunately and resoundingly successful prevention options are lacking because nearly 20–30% of patients with underlying risk factors for CIN undergoing CA go on to develop CIN. However, new treatment strategies are warranted to decrease incidence of CIN in patients undergoing CA.

In this respect, remote ischemic preconditioning (RIPC) was demonstrated in 1996. It is a novel, non-pharmacological prevention strategy inducing transient episodes of ischemia by the occlusion of blood flow in non-target tissue such as a limb before a subsequent ischemia-reperfusion injury occurs in a more distant organ. RIPC has been shown to have protective effects on the remote organs such as the heart, brain, lung, kidney, intestine or skeletal muscle via an adaptational response that protects against the ischemia and reperfusion insult. Recently, RIPC has been evaluated to prevent CIN. Even though RIPC showed protective effects on urinary liver-type fatty acid-binding protein levels in
patients with CIN, the serum creatinine levels in the RIPC and control groups did not show significant differences.\textsuperscript{3, 4} Since, there has been a lack of sufficient data regarding the protective effects of RIPC in patients at risk of developing CIN, a randomized controlled trial was conducted to determine whether RIPC as an adjunct to standard therapy prevents CIN in high-risk patients undergoing coronary intervention.

2. Methods

2.1. Study design and study population

A single-center, double-blinded, randomized controlled trial was performed at a tertiary-care center in India. A total of 162 patients were included within 12 months duration after approval from the institutional ethics committee. Patients with age \(\geq 18\) years, serum creatinine levels of \(>1.0\) mg/dL with \(\geq 2\) high risk factors based on Mehran risk factors or patients with estimated glomerular filtration rate (eGFR) levels of \(<60\) mL/min/1.73 m\(^2\) and patients undergoing selective coronary intervention either by coronary angiography or by percutaneous trans-lumious coronary angiography (PTCA) were included in the study. Patients who refused to sign the informed consent form, patients undergoing routine haemodialysis or peritoneal dialysis and patients in whom RIPC could not be performed due to pathology of both the arms (for example, dystrophy, recent trauma and chronic wounds) were excluded from the study. Signed informed consent forms were obtained from all the patients in the study.

2.2. Study procedure

The present study was initially planned in two-steps. The present first-step was designed to prove the concept that RIPC might be beneficial in patients at high-risk for CIN. Based upon the results of the present study a second extended study may be designed to test the effects of RIPC on cardiovascular mortality and morbidity. According to the standard guidelines, all participating patients received the standard hydration schedule consisting of intravenous infusion with saline 0.9\% solution of 1 ml/kg/h for 6 h before and 12 h after the contrast administration. Nephrotoxic drugs (e.g., aminoglycosides, non-steroidal anti-inflammatory drugs, and calcineurin inhibitors), and metformin were discontinued. RIPC was accomplished by performing four cycles of ischemia and reperfusion of the forearm by inflating a blood pressure cuff around the upper arm at 50 mmHg above the actual systolic pressure for 5 min, followed by 5 min of reperfusion. Ischemic preconditioning was started immediately within 3 h before patients undergoing selective coronary intervention. The sham preconditioning was performed in the same way as the RIPC, except inflating the blood pressure cuff to 10 mmHg below the actual diastolic pressure during 5 min, followed by 5 min of reperfusion. The cycle of inflation and deflation avoids bias in the Shams group. Also, inflation only till the diastolic blood pressure cannot compromise blood pressure to muscles or induce ischemia. Hence, Shams protocol serves both purposes of avoiding bias without inducing ischemia. The time between the last inflation cycle and the start of the intervention was planned to be within 45 min. In the interest of blinding, the investigator confirmed that the inflation pressure was not visible to either the patient or the interventional cardiologist.

2.3. Endpoints and definitions

The primary endpoint was a rise in serum creatinine (>0.5 mg/dL or >25\%) from baseline to serum creatinine 48–72 h after contrast administration. The secondary endpoints were the incidence of contrast-induced nephropathy (CIN) requiring rehospitalization, hemodialysis, and mortality within 6 weeks of contrast administration. CIN is defined as an absolute rise of 0.5 mg/dL or a relative increase of 25\% in serum creatinine over baseline within 48–72 h of contrast administration. The eGFR level was calculated by using the Modification of Diet in Renal Disease (MDRD) equation.

2.4. Statistical analysis

Continuous variables were expressed as mean \(\pm\) standard deviation and compared using the student’s t-test or Mann–Whitney U test. Categorical variables were expressed as frequencies and percentages and compared using the Pearson chi-square test or Fisher’s exact test. A p-value \(< 0.05\) was considered as statistically significant. The analysis was performed using Statistical Package for Social Sciences (SPSS) software version 15.0 (SPSS Inc., Chicago, Illinois, USA).

3. Results

3.1. Baseline characteristics

A total of 162 patients were included in the study. Of these, 81 were randomly allocated to receive sham preconditioning and 81 to receive RIPC. None of the patients were excluded after randomization. The two groups were matched with respect to all baseline characteristics including mean age, gender, risk factors, New York Heart Association classification, ejection fraction and type of coronary intervention. There were no statistical differences in these baseline characteristics between the sham group and RIPC group. On analyzing the risk factors for CIN it is seen that the prevalence of hypertension, diabetes, anaemia, peripheral vascular disease, prior coronary artery disease and prior myocardial infarction was similar in both the groups. On admission, the mean values of haemoglobin, volume of contrast, baseline serum creatinine and eGFR values were similar with no statistical difference between both the groups. After 48–72 h, the serum creatinine (1.44 \(\pm\) 0.21 m\(\mu\)mol/L vs. 1.35 \(\pm\) 0.21 m\(\mu\)mol/L, p = 0.007) was found to be significantly higher in the sham group than in the RIPC group. The details of the baseline characteristics are shown in Table 1.

3.2. Mehran risk score and outcome measures

In this study, Mehran low risk score [43 (53.1\%) vs. 54 (66.7\%)] was significantly higher in both the groups followed by moderate-risk [18 (22.2\%) vs. 19 (23.5\%), high risk [18 (22.2\%) vs. 6 (7.4\%)] and mild risk [2 (2.5\%) vs. 2 (2.5\%), respectively (p = 0.064). Among the patients who were classified according to their Mehran risk score, significantly reduced serum creatinine levels were observed in patients with a Mehran moderate risk allocated to the sham group than the RIPC group (0.070 \(\pm\) 0.16 mg/dL vs. 0.107 \(\pm\) 0.13 mg/dL, p = 0.001). The changes in serum creatinine per group divided by Mehran risk score are displayed in Table 2. With regards to the primary endpoint, a significantly higher change in serum creatinine from baseline to 48–72 h was observed in the sham group compared to the RIPC group (0.023 \(\pm\) 0.2 m\(\mu\)mol/L vs. –0.064 \(\pm\) 0.1 m\(\mu\)mol/L, p < 0.001). The clinical outcome measures of this study are delineated in Table 3.

4. Discussion

According to the Dutch guidelines, the current study indicates that RIPC induced by intermittent upper arm ischemia before diagnostic and therapeutic coronary procedures demonstrated a
In this study, 44.4% of patients were at high risk of developing CI-AKI, whereas Igarashi et al. included only 6% of very high-risk patients. Er et al. investigated the protective effect of RIPC in 60% of patients with a high or very high risk of developing CIN. In line with these findings, based on the reported Mehran risk score, Er et al. noted that incidence of CI-AKI should lie between 26 and 30% rather than 40% in the control group. Although the authors explained this discrepancy due to the high prevalence of heart failure and diabetes in their cohort.

Indeed, serum creatinine is not an adequate marker for CI-AKI but excretion of creatinine in urine is the result of glomerular filtration and tubular secretion. Furthermore, serum creatinine does not accurately depict kidney function until a steady-state has been reached because the levels of serum creatinine also depend on non-renal factors such as muscle mass and hydration status.

PVD — Peripheral vascular disease; CAD — Coronary artery disease; MI — Myocardial infarction; NYHA — New York Heart Association; CAG — Coronary angiography; PTCA — Percutaneous transluminal coronary angiography; eGFR — Estimated glomerular filtration rate

Table 1
Baseline characteristics.

| Variable | Sham Group (n = 81) | RIPC Group (n = 81) | p value |
|----------|---------------------|--------------------|---------|
| Age, (Mean ± SD, years) | 57.8 ± 8.0 | 55.9 ± 8.3 | 0.164 |
| Male, n (%) | 51 (63.0%) | 53 (65.4%) | 0.743 |
| **Risk factors** | | | |
| Hypertension, n (%) | 58 (71.6%) | 55 (67.9%) | 0.608 |
| Diabetes Mellitus, n (%) | 45 (55.1%) | 51 (63.0%) | 0.337 |
| Anaemia, n (%) | 3 (3.7%) | 8 (9.9%) | 0.118 |
| PVD, n (%) | 3 (3.7%) | 1 (1.2%) | 0.311 |
| Prior CAD, n (%) | 10 (12.4%) | 11 (13.6%) | 0.815 |
| Prior MI, n (%) | 12 (14.8%) | 13 (16.1%) | 0.828 |
| **Congestive heart failure (NYHA Class)** | | | |
| NYHA Class 1, n (%) | 45 (55.6%) | 43 (53.1%) | 0.331 |
| NYHA Class 2, n (%) | 26 (32.1%) | 31 (38.3%) | 0.474 |
| NYHA Class 3, n (%) | 8 (9.5%) | 3 (3.7%) | 0.070 |
| NYHA Class 4, n (%) | 2 (2.5%) | 4 (5.0%) | 0.0615 |
| **Left ventricular ejection fraction (LVEF)** | | | |
| 30–44%, n (%) | 13 (16.1%) | 11 (13.6%) | 0.808 |
| 45–59%, n (%) | 44 (54.3%) | 48 (59.3%) | 0.726 |
| ≥60%, n (%) | 24 (29.6%) | 22 (27.2%) | 0.923 |
| **Type of intervention** | | | |
| CAG, n (%) | 77 (95.1%) | 77 (95.1%) | 1.000 |
| PTCA, n (%) | 4 (4.9%) | 4 (4.9%) | 0.923 |
| Haemoglobin, (Mean ± SD, g/dL) | 12.3 ± 1.1 | 12.2 ± 1.3 | 0.067 |
| Volume of contrast, (Mean ± SD, mL) | 51.5 ± 9.1 | 52.6 ± 13.0 | 0.736 |
| Baseline serum creatinine, (Mean ± SD, μmol/L) | 1.41 ± 0.18 | 1.42 ± 0.18 | 0.631 |
| Serum creatinine (48–72 h), (Mean ± SD, μmol/L) | 1.44 ± 0.21 | 1.35 ± 0.21 | 0.007 |
| eGFR, (Mean ± SD, mL/min) | 70.71 ± 7.65 | 71.76 ± 7.08 | 0.526 |
| eGFR (48–72 h), (Mean ± SD, mL/min) | 50.17 ± 11.38 | 51.92 ± 10.56 | 0.114 |
| **Mehran risk score** | | | |
| Low risk, n (%) | 43 (53.1%) | 54 (66.7%) | 0.064 |
| Moderate risk, n (%) | 2 (2.5%) | 2 (2.5%) | 0.923 |
| High risk, n (%) | 18 (22.2%) | 19 (23.5%) | 0.923 |
| Very high risk, n (%) | 18 (22.2%) | 6 (7.4%) | 0.012 |

Table 2
Change in serum creatinine per group divided by Mehran risk score.

| Mehran Risk | N | Group | Change in serum creatinine mg/dl (Mean ± SD) | p value |
|-------------|---|-------|-------------------------------------------|---------|
| Low Risk    | 97| Sham (n = 43) | 0.006 ± 0.25 | 0.124 |
|             |   | RIPC (n = 54) | -0.061 ± 0.15 | 0.726 |
| Moderate Risk | 4| Sham (n = 2) | 0.200 ± 0.00 | 0.333 |
|             |   | RIPC (n = 2) | 0.000 ± 0.00 | 0.923 |
| High Risk   | 37| Sham (n = 18) | 0.070 ± 0.16 | 0.001 |
|             |   | RIPC (n = 19) | 0.107 ± 0.13 | 0.001 |
| Very high Risk | 24| Sham (n = 18) | -0.002 ± 0.19 | 0.923 |
|             |   | RIPC (n = 6) | 0.027 ± 0.06 | 0.923 |

* Significant.
contrast medium exposure. However, in contrast to this study, Menting et al.14 found that creatinine change in patients at high to very high risk of developing CIN was significantly lower in the RIPC group compared with those in the sham group. Unfortunately, this study did not report the incidence of serum cystatin C level. The rates of re-hospitalization, death or haemodialysis did not affect the study which is similar to a study done by Er et al.16 Nevertheless, the results of the present study support the hypothesis that RIPC reduces the incidence of creatinine based CIN in patients who are at risk of developing CIN. Thus, RIPC mediated counter-regulatory pathways may eventually offer additional clinical benefit and contribute to better clinical outcomes.

This study has some strengths. Firstly, it was performed in a tertiary-care center, and the patients were initially included in the study based on their renal dysfunction, so the protocol represents the routine daily practice in our hospital. This is why the majority of the study population had a low or moderate risk of developing CIN. Secondly, this randomized controlled trial included more patients than previous similar studies did. Lastly, this study was completely double-blinded to reduce the risk of bias. Nonetheless, the present study has a few limitations. The investigation of the beneficial effects of RIPC on renal function is a single-center trial with limited sample size. Serum creatinine levels generally raise between 48 and 72 h after contrast administration, it would have been ideal to measure creatinine levels at both 48 and 72 h.

5. Conclusion

The results from this randomized controlled trial demonstrated that the simple and well-tolerated application of RIPC in patients at risk of renal dysfunction undergoing CA reduced the incidence of procedure-related CIN. Thus, the use of RIPC may be a feasible therapeutic procedure and a large study on high-risk patients should be performed to assess the effect of RIPC as an alternate to hydration to provide additional protection in these high-risk patients.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

The authors declare that there is no conflict of interest.

Acknowledgements

None to be declared.

References

1. Zhou F, Song W, Wang Z, et al. Effects of remote ischemic preconditioning on contrast induced nephropathy after percutaneous coronary intervention in patients with acute coronary syndrome. Medicine. 2018;97(2).
2. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–936.
3. Chang C-F, Lin C-C. Current concepts of contrast-induced nephropathy: a brief review. J Chin Med Assoc. 2013;76(12):673–681.
4. Heunisch F, Chaykovska L, von Einem G, et al. ADMA predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus undergoing coronary angiography. Medicine. 2017;96(6).
5. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephropathy. Nephron Clin Pract. 2003;93(1):c29–c34.
6. Duong MH, Mackenzie TA, Malenka DJ. N-acetylcySTEINE prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Cathet Cardiovasc Interv. 2005;64(4):471–479.
7. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006;113(14):1799–1806.
8. Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation. 1997;96(5):1641–1646.
9. Gassanov N, Nia AM, Caglayan E, et al. Remote ischemic preconditioning and renoprotection: from myth to a novel therapeutic option? J Am Soc Nephrol. 2014;25(2):216–224.
10. Jensen HA, MacKenzie TD, De Waal Y, et al. Remote ischemic preconditioning to reduce contrast-induced nephropathy: a randomized controlled trial. Eur J Vasc Endovasc Surg. 2015;50(4):527–532.
11. Wdruny DJ, Mwamure PK, Venugopal V, et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet. 2007;370(9587):575–579.
12. Cheung MM, Kharbanda RK, Konstantinov IE, et al. Randomized controlled trial of the effects of remote ischemic preconditioning on children undergoing cardiac surgery: first clinical application in humans. J Am Coll Cardiol. 2006;47(11):2277–2282.
13. Igarashi G, Iino K, Watanabe H, et al. Remote ischemic preconditioning alleviates contrast-induced acute kidney injury in patients with moderate chronic kidney disease. Circ J. 2013;77(12):3037–3044.
14. Menting T, Sterenberg T, De Waal Y, et al. Remote ischemic preconditioning to reduce contrast-induced nephropathy: a randomized controlled trial. Eur J Vasc Endovasc Surg. 2015;50(4):527–532.
15. Mehra R, Aymong ED, Nikolovsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–1399.
16. Er F, Nia AM, Dopp H, et al. Ischemic preconditioning for prevention of contrast medium–induced nephropathy: randomized pilot RenPro Trial. Renal Protection Trial. Circulation. 2012;126(3):296–303.
17. Oza NM, Raman SV. Letter by Mehta Oza and Raman regarding Article “I-schemic preconditioning for prevention of contrast medium–induced nephropathy: randomized pilot RenPro trial (renal protection trial)”. Circulation. 2013;127(13). e535–e.
18. Hatano M. Clinical study of tubular creatinine secretion in renal dysfunction. Nihon Jinzo Gakkai Shi. 1991;33(11):1097–1104.
19. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomarkers Med. 2010;4(2):265–280.
20. Sudarsky D, Nikolovsky E. Contrast-induced nephropathy in interventional cardiology. Int J Nephrol Renovascular Dis. 2011;4:85.
21. Dent CL, Ma Q, Dastala S, et al. Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Crit Care. 2007;11(6):R127.